Hypoglycemia
FDA approves rescue pen for treating severe hypoglycemia
The FDA approved dasiglucagon as an auto injector or prefilled syringe for the treatment of severe hypoglycemia in people with diabetes aged 6 years and older, according to an industry press release.
Bihormonal artificial pancreas system improves time in range, reduces hypoglycemia
Adults with type 1 diabetes using a fully closed-loop, bihormonal artificial pancreas experienced improved glucose response compared with insulin pump therapy without the need to provide meal or exercise announcements, outpatient data show.
Aerobic exercise best for reducing delayed hypoglycemia risk in type 1 diabetes
Exercise modalities have varying effects in long-term glycemic response for adults with type 1 diabetes, and aerobic exercise may be the best approach to reduce the risk for delayed hypoglycemic events, according to study data.
Most adults with diabetes open to remote digital monitoring
Nearly two-thirds of adults with diabetes said they would be willing to adopt remote digital monitoring if the method was just as or more effective than their current monitoring, according to study data.
Top in endocrinology: Generic glucagon, fish consumption and diabetes risk
The FDA approval of generic glucagon for the treatment of severe hypoglycemia was the top story in endocrinology last week.
FDA approves generic glucagon for treating severe hypoglycemia
The FDA has approved the first generic glucagon for injection, commonly used to treat severe hypoglycemia in individuals with diabetes taking insulin, according to an agency press release.
No causal link between severe hypoglycemia, increased mortality in type 2 diabetes
Severe hypoglycemic episodes are a marker of, rather than causally related to, an increased risk for death among adults with type 2 diabetes, according to data published in Diabetologia.
Investigational once-daily pill reduces HbA1c in type 1 diabetes, without hypoglycemia
An investigational once-daily pill added to optimized insulin therapy was shown to reduce HbA1c among adults with type 1 diabetes during a 12-week trial when compared with placebo plus insulin, according to a presenter.
Smart insulin pens address challenges of multiple daily injection therapy
In this issue, Susan Weiner, MS, RDN, CDN, CDCES, FADCES, talks with nurse practitioner and diabetes care and education specialist Colleen Miller-Owen, MSN, APRN, CDCES, about the benefits of smart insulin pens for multiple daily injections.
Once-weekly insulin efficacy similar to daily therapy in type 2 diabetes
Adults with type 2 diabetes assigned an investigational once-weekly insulin therapy experienced a decrease in HbA1c similar to that seen with daily insulin glargine, according to findings from a phase 2 randomized controlled trial.